Literature DB >> 21975932

EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction.

Xun Jin1, Jinlong Yin, Sung-Hak Kim, Young-Woo Sohn, Samuel Beck, Young Chang Lim, Do-Hyun Nam, Yun-Jaie Choi, Hyunggee Kim.   

Abstract

Aberrant activation of receptor tyrosine kinases (RTK) is causally linked to the pathobiological traits of glioblastoma and genesis of glioma stem-like cells (GSC), but the underlying mechanism is still unknown. Here, we show that epidermal growth factor receptor (EGFR) signaling regulates the proliferation, angiogenesis, and acquisition of GSC characteristics by inducing inhibitor of differentiation 3 (ID3) and ID3-regulated cytokines [GRO1 and interleukins (IL)-6 and 8] induction. We found that EGFR-mediated ID3 expression was regulated by Smad5, which was directly phosphorylated by AKT. Furthermore, ID3 alone imparted GSC features to primary astrocytes derived from Ink4a/Arf-deficient mouse, and EGFR-ID3-IL-6 signaling axis gave rise to tumor cell heterogeneity. Conversely, EGFR inhibitors suppressed EGFR-AKT-Smad5-driven induction of ID3, which led to a decrease in the tumorsphere forming ability of GSCs and U87MG cells that possess an active mutant EGFR, EGFRvIII, without obvious cytotoxic effects. However, these cells seemed to regain colonogenic ability after removal of the EGFR inhibitors. Together, the results delineate a novel integrative molecular mechanism in which the RTK-ID signaling pathway governs genesis and maintenance of GBM histopathologic features, such as GSCs-based tumor initiation, progression, and angiogenesis. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975932     DOI: 10.1158/0008-5472.CAN-11-1330

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

1.  ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases.

Authors:  Jayanta K Das; Norbert F Voelkel; Quentin Felty
Journal:  Microvasc Res       Date:  2015-02-07       Impact factor: 3.514

Review 2.  Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

Authors:  T E Taylor; F B Furnari; W K Cavenee
Journal:  Curr Cancer Drug Targets       Date:  2012-03       Impact factor: 3.428

3.  Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Authors:  Szu-Ting Chou; Rameshwar Patil; Anna Galstyan; Alexander V Ljubimov; Julia Y Ljubimova; Pallavi R Gangalum; Webster K Cavenee; Frank B Furnari; Vladimir A Ljubimov; Alexandra Chesnokova; Andrei A Kramerov; Hui Ding; Vida Falahatian; Leila Mashouf; Irving Fox; Keith L Black; Eggehard Holler
Journal:  J Control Release       Date:  2016-11-05       Impact factor: 9.776

Review 4.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

5.  Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Authors:  Jun Fu; Dimpy Koul; Jun Yao; Shuzhen Wang; Ying Yuan; Howard Colman; Erik P Sulman; Frederick F Lang; W K Alfred Yung
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

6.  Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis.

Authors:  Francesco Niola; Xudong Zhao; Devendra Singh; Ryan Sullivan; Angelica Castano; Antonio Verrico; Pietro Zoppoli; Dinorah Friedmann-Morvinski; Erik Sulman; Lindy Barrett; Yuan Zhuang; Inder Verma; Robert Benezra; Ken Aldape; Antonio Iavarone; Anna Lasorella
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

Review 7.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

8.  EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Swapna Asuthkar; Bharathi Gorantla; Andrew J Tsung
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

9.  Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Authors:  Esther A Suswam; John J Shacka; Kiera Walker; Liang Lu; Xuelin Li; Ying Si; Xiaowen Zhang; Lei Zheng; L Burt Nabors; Heping Cao; Peter H King
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

10.  Rab3a promotes brain tumor initiation and progression.

Authors:  Jun-Kyum Kim; Seung-Yup Lee; Chang-Won Park; Suk-Hwang Park; Jinlong Yin; Jaebong Kim; Jae-Bong Park; Jae-Yong Lee; Hyunggee Kim; Sung-Chan Kim
Journal:  Mol Biol Rep       Date:  2014-06-26       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.